Exelixis, Inc. (NASDAQ:EXEL) Stake Decreased by Renaissance Technologies LLC

Renaissance Technologies LLC trimmed its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 0.4% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 15,295,865 shares of the biotechnology company's stock after selling 64,051 shares during the quarter. Exelixis comprises approximately 0.8% of Renaissance Technologies LLC's portfolio, making the stock its 9th biggest position. Renaissance Technologies LLC owned about 5.36% of Exelixis worth $509,352,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Rathbones Group PLC bought a new position in shares of Exelixis during the 4th quarter valued at $216,000. Invesco Ltd. increased its position in Exelixis by 308.1% during the fourth quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company's stock valued at $132,376,000 after acquiring an additional 3,001,204 shares during the last quarter. Cerity Partners LLC lifted its holdings in Exelixis by 163.9% in the fourth quarter. Cerity Partners LLC now owns 73,884 shares of the biotechnology company's stock valued at $2,413,000 after acquiring an additional 45,890 shares during the period. FMR LLC boosted its position in Exelixis by 19.7% in the fourth quarter. FMR LLC now owns 2,947,599 shares of the biotechnology company's stock worth $98,155,000 after purchasing an additional 485,527 shares during the last quarter. Finally, Federated Hermes Inc. grew its stake in shares of Exelixis by 82.9% during the 4th quarter. Federated Hermes Inc. now owns 408,932 shares of the biotechnology company's stock valued at $13,637,000 after purchasing an additional 185,389 shares during the period. Hedge funds and other institutional investors own 85.27% of the company's stock.

Remove Ads

Analysts Set New Price Targets

EXEL has been the topic of several recent research reports. JMP Securities reiterated a "market outperform" rating and issued a $41.00 price objective on shares of Exelixis in a research note on Thursday, January 23rd. Citigroup increased their price target on shares of Exelixis from $38.00 to $45.00 and gave the stock a "buy" rating in a research report on Wednesday, February 12th. HC Wainwright reissued a "buy" rating and set a $40.00 price objective on shares of Exelixis in a research report on Thursday, March 27th. Wells Fargo & Company cut Exelixis from an "overweight" rating to an "equal weight" rating and set a $36.00 target price on the stock. in a report on Monday, February 24th. Finally, Royal Bank of Canada boosted their price target on Exelixis from $38.00 to $40.00 and gave the company an "outperform" rating in a report on Thursday, March 13th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $37.59.

Insider Activity

In other news, Director Jack L. Wyszomierski sold 8,768 shares of the company's stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $37.80, for a total transaction of $331,430.40. Following the sale, the director now directly owns 356,605 shares in the company, valued at approximately $13,479,669. This represents a 2.40 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Patrick J. Haley sold 10,000 shares of Exelixis stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $38.80, for a total value of $388,000.00. Following the completion of the transaction, the executive vice president now owns 341,028 shares of the company's stock, valued at approximately $13,231,886.40. This represents a 2.85 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 140,343 shares of company stock worth $5,177,234. 2.85% of the stock is currently owned by insiders.

Exelixis Stock Up 2.5 %

EXEL stock traded up $0.85 during mid-day trading on Friday, hitting $35.31. The company had a trading volume of 2,146,139 shares, compared to its average volume of 2,175,271. The company has a 50-day moving average price of $36.16 and a 200 day moving average price of $34.01. Exelixis, Inc. has a 12-month low of $20.14 and a 12-month high of $40.02. The company has a market capitalization of $9.88 billion, a price-to-earnings ratio of 19.95, a P/E/G ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. As a group, analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.